After meeting with management, Cantor Fitzgerald analyst Brandon Folkes calls Chiasma a top idea for the second half of 2019. The analyst reiterates an Overweight rating on the shares with an $18 price target. Based on the totality of evidence from CH-ACM-01 and the MPOWERED six-month run-in phase, there is a high likelihood of OPTIMAL reporting responder rates in the 50-%60% range, Folkes tells investors in a research note. However, the bar for a successful trial readout is "meaningfully lower" in the ~30% range, provided the result is statistically significant, adds the analyst. He expects data readouts, approvals, and upward earnings revisions to drive Chiasma shares higher.